-
Pharmaceutical Giants Race to Integrate DeepSeek AI for Efficiency Gains
•
On February 14, China’s stock market saw a significant upsurge in the AI pharmaceuticals sector, with healthcare stocks across the board performing strongly. The rally was particularly driven by AI Pharmaceuticals, medical services, and DRG/DIP segments, with companies like Shanghai Runda Medical Technology Co., Ltd. leading the charge, resulting in…
-
ClouDr Receives NMPA Green Light for ClouDT-01, a Groundbreaking Digital Diabetes Treatment
•
Hangzhou Kang Ming Information Technology Co., Ltd, trading under the banner of “ClouDr” on the Hong Kong stock exchange (HKG: 9955), has announced that it has secured marketing approval from the National Medical Products Administration (NMPA) for its innovative digital medicine product, ClouDT-01, designed for the treatment of diabetes. Leveraging…
-
Hangzhou Kang Ming’s ClouDr Posts Strong Financial Growth with Diversified Solutions and P2M Strategy
•
Hangzhou Kang Ming Information Technology Co., Ltd, trading under the moniker “ClouDr” on the Hong Kong Stock Exchange (HKG: 9955), has reported its financial results for the first half of 2024, demonstrating a robust year-on-year (YOY) increase of 17.9%, with total revenues reaching RMB 2.125 billion (USD 298 million). The…
-
ClouDr Secures Exclusive Sub-Licensing Rights for Iloprost Infusion Solution
•
Hangzhou Kang Ming Information Technology Co., Ltd (HKG: 9955), operating under the brand name “ClouDr,” has announced a licensing agreement with Clinect Pty Ltd as the licensor and Bluefly Consulting Limited as the seller. ClouDr has secured exclusive sub-licensing rights for the development, manufacturing, promotion, publicity, distribution, and marketing of…
-
ClouDr Launches Dapagliflozin, Generic Version of AstraZeneca’s Forxiga, After NMPA Approval
•
Hangzhou Kang Ming Information Technology Co., Ltd. (HKG: 9955), known as “ClouDr,” has officially launched dapagliflozin, its self-operated product with marketing rights. This drug serves as a generic version of AstraZeneca (NASDAQ: AZN)’s Forxiga, a leading treatment for type 2 diabetes. The approval for dapagliflozin was secured through Nanjing F&S…
-
ClouDr Inks Deal with CR Sanjiu to Boost Hospital Sales of Cardiovascular Medicine
•
Hangzhou Kang Ming Information Technology Co., Ltd, (HKG: 9955) trading under the moniker “ClouDr”, has entered into a partnership with CR Sanjiu (SHE: 000999), a state-owned pharmaceutical company specializing in treatments for cardiovascular and cerebrovascular diseases and endocrine disorders. Under this strategic alliance, ClouDr will serve as the general agent…
-
ClouDr Partners with Yangtze River Pharmaceutical to Digitize Chronic Disease Marketing
•
Hangzhou Kang Ming Information Technology Co., Ltd, trading as “ClouDr” (HKG: 9955), has entered into a partnership with fellow Chinese company Yangtze River Pharmaceutical (Group) Co., Ltd. The collaboration will concentrate on providing digitalized marketing services within specific chronic disease sectors, with both parties looking to expand and deepen their…
-
ClouDr Partners with Hong Kong Magicure Medical Center to Enhance Cross-Border Medical Access
•
Hangzhou Kang Ming Information Technology Co., Ltd, known as “ClouDr” (HKG: 9955), has entered into a partnership with Hong Kong Magicure Medical Center with the goal of streamlining the supply chain and accelerating domestic access to the world’s leading medical resources in China. This collaboration aims to provide patients with…
-
ClouDr Partners with Banbiantian to Digitalize Medicine and Medical Device Sector
•
Hangzhou Kang Ming Information Technology Co., Ltd, trading under the name “ClouDr” (HKG: 9955), has entered into a strategic partnership with Wuhan Banbiantian Medical Technology Development Co., Ltd. The collaboration, which is centered around digitalization technologies, is designed to capitalize on the “medicine, device, drug” linkage model. While financial specifics…
-
ClouDr Partners with Shaanxi Pharmaceutical Firms for Integrated Healthcare Solutions
•
Hangzhou Kang Ming Information Technology Co., Ltd (HKG: 9955), better known as “ClouDr,” has announced a strategic partnership with compatriot firms Shaanxi Pharmaceutical Holding Group Co., Ltd and Shaanxi Pharmaceutical Holding Pai Ang. The collaboration aims to leverage the respective resources and expertise of the three companies to enhance drug…
-
ClouDr Partners with Ipsen to Expand Diphereline’s Reach in China
•
Hangzhou Kang Ming Information Technology Co., Ltd (HKG: 9955), known as “ClouDr,” has partnered with French pharmaceutical company Ipsen S.A. (Euronext: IPN; ADR: IPSEY) regarding Ipsen’s Diphereline (triptorelin), a natural gonadotropin-releasing hormone (GnRH) agonist analog. Financial details of the partnership were not disclosed. ClouDr is a one-stop chronic disease management…
